1 / 47

URINARY INCONTINENCE

PRIYA VASUDEVAN MD PGY 2. URINARY INCONTINENCE. OBJECTIVES. Identify the various forms of Urinary Incontinence (UI) To become knowledgeable about the treatment interventions available To understand the impact of Urinary Incontinence. DEFINITION.

Télécharger la présentation

URINARY INCONTINENCE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PRIYA VASUDEVAN MD PGY 2 URINARY INCONTINENCE

  2. OBJECTIVES • Identify the various forms of Urinary Incontinence (UI) • To become knowledgeable about the treatment interventions available • To understand the impact of Urinary Incontinence

  3. DEFINITION • Incontinence: “Involuntary loss of urine or stool in sufficient amount or frequency to constitute a social and/or health problem. A heterogeneous condition that ranges in severity from dribbling small amounts of urine to continuous urinary incontinence…”

  4. Urinary Incontinence is Often Under-Diagnosed and Under-Treated • Only 32% of primary care physicians routinely ask about incontinence. • Often not mentioned to physicians • 50-75% of patients never describe symptoms to physicians • 80% of urinary incontinence can be cured or improved.

  5. Prevalence of Urinary Incontinence • Affects 13 million Americans • 33% of women >65 have some degree of UI • 26% of women>18 experience various degree of SI • 15% to 30% of noninstitutionalized older adults (19% men; 39% women) • Prevalence increases with age (not normal aging) • 50% of those in nursing facilities

  6. Economic Costs • 10 billion $ in 1987 • Costs of UI in 1995 is 24.3 billion or $ 3,561 per incontinence person. • 32.1 billion $ in 2000 for UI and OAB • Cost: physical, psychological and social impact

  7. Anatomy of Micturition • Detrusor Muscle • External and Internal sphincter • Normal capacity 300- 600 cc • First urge to void150-300 cc • Parasympathetic-Bladder contracts • Sympathetic- Bladder relaxes and Bladder neck and urethral contraction. • Somatic- Pudendal nerve –contraction of pelvic floor muscle

  8. Nerves and Micturition

  9. Risk and Contributing Factors • Age • Parity • Obesity • Vaginal delivery • Episiotomy • Diabetes • Stroke • Estrogen depletion • Genitourinary surgery and radiation

  10. TYPES OF URINARY INCONTINENCE • Urge Incontinence – Strong urge to void immediately( with or without increased frequency) • Stress incontinence – Increased intra-abdominal pressure that leads to incontinence • Overflow Incontinence – Over distended bladder leading to UI/dribbling • Functional Incontinence – Physical/Psychological impairment due to inability to get to BR • Mixed Incontinence – Combination of 2 or more types

  11. STRESS INCONTINENCE • Most common type in women in < 75 years old • Occurs with increase in abdominal pressure- cough, laugh, sneeze, etc • Hyper motility of bladder neck and urethra associated with aging, child birth, hormonal changes • Intrinsic sphincter problems( pelvic irradiation, surgery, trauma, incontinence surgery) • No urgency or nocturia

  12. STRESS INCONTINENCE

  13. URGE INCONTINENCE • OAB, Detrusor instability, irritable bladder, detrusor hyperactivity. • Most common UI > 75 years of age • Abrupt desire to void urine cannot be suppressed • Associated with frequency / nocturia. • Causes- infection, vaginitis, tumor, stones, MS, idiopathic

  14. URGE INCONTINENCE

  15. GOTTA GO, GOTTA GO!!!!!!!!

  16. OVERFLOW INCONTINENCE • Over Distension of Bladder • Bladder outlet obstruction- Stricture, BPH, Cystocele, fecal impaction • Non contractile bladder- Diabetes, MS, Spinal injury. • Filling occurs to the stretch limit of the bladder • Large PVR >400cc • Dribbling, frequency • High rates of infections

  17. FUNCTIONAL INCONTINENCE Does not involve lower urinary tract Result of psychological, cognitive or physical impairment

  18. MIXED INCONTINENCE

  19. REVERSIBLE CAUSES • D- Delirium • I - Infection • A-Atrophic Vaginitis • P- Pharmaceuticals/ Psychological • E- Endocrine • R- Restricted mobility • S- Stool impaction

  20. EVALUATION OF INCONTINENCE • History • Physical exam ( including Neuro and abdominal , pelvic and rectal examination) • Clinical testing- Stress test, PVR by catheterization or ultrasound. • Laboratory testing- UA, Urine culture, Blood test. • URODYNAMIC TESTING

  21. TAKING THE HISTORY • Duration, Symptoms, Severity, nocturnal symptoms, no . Of pads per day. • Medical and surgical history • Medications • Social history • Bladder diary • Record the time and volume • Number of voiding • Number of pads • Incontinence episode • Severity of the problem • Time of the day with increased frequency.

  22. KEY QUESTIONS • Are you leaking urine ? • Do you have trouble making it to the bathroom? • Do you go to the BR frequently? • Do you leak urine when coughing, laughing or sneezing • Do you wear pads for urine leakage? • How many times do you wake up at night?

  23. BLADDER DIARY

  24. CLINICAL TESTS • Stress test • Post void residual volume

  25. LABORATORY TESTS • UA • Urine culture if infection is suspected. • Urine Cytology if hematuria +, pelvic pain • Kidney function tests • Calcium and glucose testing. • Vitamin B12 • PSA • REFERRAL for URODYNAMIC STUDY in refractory cases.

  26. TREATMENT OF UI • Lifestyle Modifications including weight loss, dietary changes. • Behavioral therapy are effective in urge, stress and mixed incontinence and should be the initial treatment. • Medications • Devices • REFERRAL for further investigation and Surgery

  27. LIFE STYLE MODIFICATION • Weight loss • Dietary Changes • alcoholic beverages • carbonated beverages • coffee or tea(with or without caffeine) • citrus juice, tomatoes, chocolate, spicy foods, artificial sweetener.

  28. BEHAVIORAL TREATMENT • STRESS INCONTINENCE • Patient education • Pelvic muscle exercises • Diet modification • Weighted vaginal cones • Pessary • Pelvic floor electrical stimulation • Weight reductions • URGE INCONTINENCE • Patient education • Timed voiding • Habit training • urge inhibition • bladder training • Pelvic muscle exercises • Diet modification

  29. BEHAVIORAL TREATMENT • MIXED INCONTINENCE • Patient education • Treat the predominant type • Kegel exercises-81% reduction in urinary leakage • Diet modification • Bladder training • OVERFLOW INCONTINENCE • Patient education • “Double voiding technique” • Diet modification • Avoid caffeine/alcohol • Barrier product to prevent skin breakdown

  30. BEHAVIORAL TREATMENT • FUNCTIONAL INCONTINENCE • Patient education • Environment alterations • Grab bars/raised seats • Caregiver assistance/education • Screen for depression/cognitive impairment • Occupational /Physical therapy

  31. PELVIC MUSCLE EXERCISES • Kegel exercises are used for Urge, stress and mixed incontinence • Recommended regimen is 3 sets of 8 to 12 slow velocity Ctxs sustained for 6 to 8 secs each performed 3-4 times a week and continued for at least 15-20 weeks.

  32. PHARMACOTHERAPY • Anticholinergics=detrusor underactivity, may cause retention • Cholinergics=detrusor overactivity, may cause frequency • Alpha agonists=outlet overactivity, may cause retention • Alpha blockers=outlet underactivity, may cause stress incontinence

  33. ANTICHOLINERGICS • Darifenacin (Enablex) • Oxybutynin (Ditropan, DitropanXL,Oxytrol) • Solifenacin (Vesicare) • Tolterodine (Detrol, Detrol LA) • Trospium (Sanctura) • Flavoxate (Urispas)

  34. OTHER MEDICATIONS IN URGE INCONTINENCE • Bethanechol (Urecholine)( used to treat underactive detrusor function with elevated PVR) • Dicyclomine an antispasmodic. • TCA- Imipramine in mixed incontinence. • Duloxetine ( approved by the EU for treatment of SI. • Estrogen- No clear role for topical estrogen • Oral estrogen should not be prescribed for urinary incontinence in post menopausal woman. • Botox Not yet approved fby FDA, off label use for refractory urge incontinence.

  35. ALPHA AGONISTS • Stimulates urethral smooth muscle contraction and have been used in the Rx for stress incontinence. • Phenylpropanolamine hydrochloride-no longer marketed in U.S. (Intracerebral hemorrhage) • Pseudoephedrine (Sudafed) • Midodrine (Proamatine

  36. ALPHA BLOCKERS & 5 ALPHA REDUCTASE INHIBITORS • Are effective in men with OAB symptoms associated with BPH. • Alfuzosin (Uroxatral) • Doxazosin (Cardura) • Tamsulosin (Flomax) • Terazosin (Hytrin • Finasteride(Proscar)

  37. KEY RECOMMENDATIONS

  38. REFERRAL • Failure to respond to treatment • Appearance of new symptoms • Microscopic hematuria in the absence of infection • Severe prolapse • Neurological symptoms

  39. OTHER TREATMENT OPTIONS • Electrical stimulation therapies for UI • Small removable device placed in either the vagina or anus • SNS is used for refractory urge UI, refractory urgency-frequency and idiopathic non- obstructive urinary retention • Intravesical stimulation • PC stimulation of tibial nerve.

  40. SURGICAL TREATMENT • Indications: • Failed nonsurgical management • Unable to tolerate side effects of medications • More definitive therapy

  41. SURGERY Contd • Surgery offers the highest cure rates for stress UI • Burch colposuspension • Sling procedures • Periurethral bulking injection with collagen

  42. ADJUNCTIVE MEASURES • Pads and protective garments • Continence pessaries • Catheter (indwelling or intermittent )

  43. References • Wilson L obstetrics and gynec 2001 • Wagner, Urology 1998; 51:355 • 355-61.,2004 • Resnick, JAMA 1998; 280:2034 • 2034-5. • Hendrix, Disease • Disease-A-Month, 2002; 48:622 622-636. • Management recommendations, In: Abrams, P, cardozo, L Khoury, S Wein, A. Incontinence 4 th international consultation on incontinence • Wallace , SA Roe, b Williams,K, Palmer, M,cochrane database sys review 2004; CD001308.

More Related